Tocilizumab treatment in COVID-19 patients: therapy's side effects and effect on mortality
Description
CONCLUSIONS: Despite the risks of side effects, tocilizumab was used in COVID-19 treatment since it is an interleukin-6 blocker. Although the first publications stated that the treatment could decrease the mortality rate, later meta-analyses did not
